0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Treatment of Condyloma Acuminatum with Three Different Interferons Administered lntralesionally: A Double-Blind, Placebo-Controlled Trial

RICHARD C. REICHMAN, M.D.; DAVID OAKES, Ph.D.; WILLIAM BONNEZ, M.D.; CAROL GREISBERGER, R.N.; STEVEN TYRING, M.D.; LISA MILLER, R.N.; RICHARD WHITLEY, M.D.; HOLLY CARVETH, M.D.; MELISSA WEIDNER, R.N.; GERALD KRUEGER, M.D.; LORI YORKEY, B.A.; NORBERT J. ROBERTS Jr., M.D.; and RAPHAEL DOLIN, M.D.
[+] Article and Author Information

Grant support: in part by grant NO1-AI-32510 from the National Institute of Allergy and Infectious Diseases and grant RR032 from the Division of Research Resources. William Bonnez, M.D., is the recipient of a Wilmot Cancer Research Fellowship.

▸Requests for reprints should be addressed to: Richard C. Reichman, M.D.; University of Rochester School of Medicine, Infectious Diseases Unit, P.O. Box 689, 601 Elmwood Avenue; Rochester, NY 14642.


Rochester, New York; Birmingham, Alabama; and Salt Lake City, Utah


© 1988 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1988;108(5):675-679. doi:10.7326/0003-4819-108-5-675
Text Size: A A A

Study Objective: To determine the efficacy and toxicity of intralesionally administered interferons in the treatment of condyloma acuminatum.

Design: Randomized, double-blind, and placebo-controlled study.

Setting: Outpatient clinics at university medical centers.

Patients: Seventy-nine patients with biopsy-proved condyloma acuminatum that was refractory to conventional therapy were enrolled in the study.

Interventions: Alpha-2b-, alpha-nl-, and beta-interferons were used. One wart on each patient was injected three times per week for 4 weeks with either 1x106 units of interferon or placebo.

Measurements and Main Results: Forty-seven percent of warts injected with interferon resolved completely, compared with 22% of placebo-injected warts (P = 0.009). In addition, more recipients of interferon had a complete resolution of uninjected lesions. No differences in rates of response were noted among the different interferon groups. Approximately one third of interferon-injected warts recurred, compared with none of four placebo-injected warts. Intralesionally administered interferon was nontoxic and well tolerated, although transient pain on injection was observed frequently.

Conclusions: Intralesional administration of each of these three interferons appears to be useful in treating condyloma acuminatum. However, the frequent recurrence of disease and the failure of many lesions to resolve indicate that different regimens, such as longer courses of therapy or different routes of administration, should be evaluated to maximize beneficial effects of interferon for treating this common sexually transmitted disease.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)